• Industry News
  • Law & Malpractice
  • Coding & Documentation
  • Practice Management
  • Finance
  • Technology
  • Patient Engagement & Communications
  • Billing & Collections
  • Staffing & Salary

Calculating Buy-In

Article

We are gathering financial data for our accountant so that he can determine the buy-in for an associate on a partnership track. He’s asking for an aged report for January 2007 through October 2007. We still have A/R from 2006 that we’re working on - some of it, of course, will be uncollectible, but the rest might be, even if at a lower rate than normal. Shouldn’t that be considered into the value as well? Is there a “formula” to take older A/R into consideration?

Question: We are gathering financial data for our accountant so that he can determine the buy-in for an associate on a partnership track. He’s asking for an aged report for January 2007 through October 2007. We still have A/R from 2006 that we’re working on - some of it, of course, will be uncollectible, but the rest might be, even if at a lower rate than normal. Shouldn’t that be considered into the value as well? Is there a “formula” to take older A/R into consideration?

Answer: Well, if I were the physician about to buy in, I’d sure balk at having A/R that old pulled into the equation at full value.

That said, I have seen practices count it at a reduced percentage. For example, say there is $10,000 outstanding. Only 5 percent of anything older than 120 days would be counted. This might be a good opportunity to clean up that backlog. Anything older than 14 months and owned by a payer should really be written off. Go ahead and tackle some of the more recent and bigger patient accounts and see what happens. That'll give you a sense of how realistic it is to include this as A/R.

You also might consider setting a policy for how long accounts stay on the books.

Related Videos
The importance of vaccination
The fear of inflation and recession
Protecting your practice
Protecting your home, business while on vacation
Protecting your assets during the 100 deadly days
Payment issues on the horizon
The future of Medicare payments
MGMA comments on automation of prior authorizations
The burden of prior authorizations
Strategies for today's markets
© 2024 MJH Life Sciences

All rights reserved.